Lv3
280 积分 2022-08-18 加入
The 6Ps of Preparing a Manuscript: Prior Preparation Prevents Potentially Poor Performance
2天前
已完结
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study
15天前
已完结
P4.11E.05 A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC
15天前
已关闭
Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial
23天前
已完结
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial
23天前
已完结
Donanemab in Early Symptomatic Alzheimer Disease
1个月前
已完结
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study
1个月前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
1个月前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
1个月前
已完结
Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study
2个月前
已完结
皖公网安备34019202002308
